AR100768A1 - Método para disminuir la inmunogenicidad de proteínas y péptidos - Google Patents

Método para disminuir la inmunogenicidad de proteínas y péptidos

Info

Publication number
AR100768A1
AR100768A1 ARP150101804A ARP150101804A AR100768A1 AR 100768 A1 AR100768 A1 AR 100768A1 AR P150101804 A ARP150101804 A AR P150101804A AR P150101804 A ARP150101804 A AR P150101804A AR 100768 A1 AR100768 A1 AR 100768A1
Authority
AR
Argentina
Prior art keywords
peptide
physiologically active
vehicle
active protein
immunogenicity
Prior art date
Application number
ARP150101804A
Other languages
English (en)
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR100768A1 publication Critical patent/AR100768A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Vascular Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Reivindicación 1: Un procedimiento para disminuir la inmunogenicidad de una proteína o péptido fisiológicamente activos en comparación con aquella de una proteína o péptido fisiológicamente activos a los que no está unido un vehículo, que comprende unir un vehículo al residuo interno, no terminal de la proteína o péptido fisiológicamente activos. Reivindicación 14: Una composición, que comprende un conjugado de una proteína o péptido fisiológicamente activos en el que un vehículo está unido al residuo interno, no terminal de una proteína o péptido fisiológicamente activos, a través de un conector no peptidilo, en el que el conjugado exhibe inmunogenicidad disminuida en comparación con aquella de la proteína o péptido fisiológicamente activos al que el vehículo no está unido. Reivindicación 16: La composición de acuerdo a la reivindicación 14, en el que el conector no peptidilo es un polietilenglicol.
ARP150101804A 2014-06-05 2015-06-05 Método para disminuir la inmunogenicidad de proteínas y péptidos AR100768A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140068660A KR20150140177A (ko) 2014-06-05 2014-06-05 단백질 및 펩타이드의 면역원성을 감소시키는 방법

Publications (1)

Publication Number Publication Date
AR100768A1 true AR100768A1 (es) 2016-11-02

Family

ID=54767003

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101804A AR100768A1 (es) 2014-06-05 2015-06-05 Método para disminuir la inmunogenicidad de proteínas y péptidos

Country Status (20)

Country Link
US (2) US20170100488A1 (es)
EP (2) EP4219565A1 (es)
JP (2) JP7125249B2 (es)
KR (3) KR20150140177A (es)
CN (1) CN106661118A (es)
AR (1) AR100768A1 (es)
AU (1) AU2015269039B2 (es)
BR (1) BR112016028227A2 (es)
CA (1) CA2950576A1 (es)
EA (1) EA035964B1 (es)
HU (1) HUP1700024A2 (es)
IL (1) IL249131A0 (es)
MX (2) MX2016015668A (es)
MY (1) MY193519A (es)
NO (1) NO20161980A1 (es)
PH (1) PH12016502430A1 (es)
SG (2) SG11201610098YA (es)
TW (1) TW201625314A (es)
UA (1) UA124183C2 (es)
WO (1) WO2015186988A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
SG10202107752PA (en) * 2014-03-31 2021-09-29 Hanmi Pharmaceutical Co Ltd Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
JP2019532019A (ja) * 2016-07-22 2019-11-07 ネクター セラピューティクス オキシム含有リンケージを有する第ｖｉｉｉ因子部分のコンジュゲート
WO2018105988A1 (ko) * 2016-12-05 2018-06-14 한미약품 주식회사 면역반응이 약화된 결합체
BR112019016077A2 (pt) * 2017-02-03 2020-03-31 Hanmi Pharm. Co., Ltd. Conjugado da fórmula 1, método para preparar o conjugado, preparação de atuação longa, preparação para prevenir ou tratar diabetes e método para tratar diabetes
WO2019036631A1 (en) * 2017-08-18 2019-02-21 The Johns Hopkins University SUPRAMOLECULAR FILAMENT ASSEMBLIES FOR THE PURIFICATION OF PROTEINS
MX2020002070A (es) 2017-08-22 2020-03-24 Sanabio Llc Receptores solubles de interferon y usos de los mismos.
CN111406073A (zh) * 2017-09-29 2020-07-10 韩美药品株式会社 具有提高功效的持久性蛋白质缀合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
PT1438966E (pt) * 1999-12-08 2007-05-31 Cyclacel Pharmaceuticals Inc Uso de depsipéptidos e seus congéneres como imunosupressores para tratamento de doenças infecciosas, como uma doença autoimune, reacções alérgicas ou doença hiperproliferativa da pele.
ES2382636T3 (es) * 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Método para producir composiciones para la administración mejorada de moléculas bioactivas
BR0207267A (pt) * 2001-02-19 2004-02-10 Merck Patent Gmbh Proteìnas artificiais com imunogenicidade reduzida
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US8420598B2 (en) * 2007-04-20 2013-04-16 B & L Delipharm Corp. Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
KR101164453B1 (ko) * 2009-03-20 2012-07-11 한미사이언스 주식회사 위치특이적 생리활성 폴리펩타이드 결합체의 제조방법
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
ES2968043T3 (es) 2011-06-10 2024-05-06 Hanmi Science Co Ltd Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de la obesidad que comprende la misma
JP2012256007A (ja) 2011-06-10 2012-12-27 Nippon Zeon Co Ltd パターン位相差フィルム用液晶組成物、パターン位相差フィルム及び立体表示装置
KR101577734B1 (ko) 2011-06-17 2015-12-29 한미사이언스 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도
KR20140088837A (ko) 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
PT2963056T (pt) 2013-02-26 2020-02-19 Hanmi Pharm Ind Co Ltd Análogo de insulina e utilização do mesmo
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법

Also Published As

Publication number Publication date
JP2017521381A (ja) 2017-08-03
EP3152236A1 (en) 2017-04-12
PH12016502430A1 (en) 2017-03-06
US20170100488A1 (en) 2017-04-13
UA124183C2 (uk) 2021-08-04
MX2021006021A (es) 2021-07-06
CN106661118A (zh) 2017-05-10
JP7125249B2 (ja) 2022-08-24
MX2016015668A (es) 2017-02-27
WO2015186988A1 (en) 2015-12-10
BR112016028227A2 (pt) 2017-10-24
IL249131A0 (en) 2017-01-31
KR20150140177A (ko) 2015-12-15
SG11201610098YA (en) 2016-12-29
AU2015269039B2 (en) 2020-12-10
AU2015269039A1 (en) 2016-12-08
EP4219565A1 (en) 2023-08-02
US20220118103A1 (en) 2022-04-21
CA2950576A1 (en) 2015-12-10
MY193519A (en) 2022-10-17
EA035964B1 (ru) 2020-09-07
JP2021028329A (ja) 2021-02-25
SG10202104313PA (en) 2021-06-29
KR20210111190A (ko) 2021-09-10
KR20230023691A (ko) 2023-02-17
EA201692279A1 (ru) 2017-05-31
HUP1700024A2 (en) 2017-05-29
EP3152236A4 (en) 2018-07-04
NO20161980A1 (en) 2016-12-14
TW201625314A (zh) 2016-07-16

Similar Documents

Publication Publication Date Title
AR100768A1 (es) Método para disminuir la inmunogenicidad de proteínas y péptidos
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
CO2018000303A2 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
TW201613958A (en) MIC-1 fusion proteins and uses thereof
EA201892671A1 (ru) Пегилированный свиной интерферон и способы его применения
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
EP4285928A3 (en) Anti-pdl1 antibody formulations
WO2017077085A3 (en) Immunomodulatory antibodies
EP3889185A3 (en) Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage
CL2016001405A1 (es) A peptide mixture
PE20230404A1 (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
EA201792245A1 (ru) Биоконъюгаты и их применения
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
UA118167C2 (uk) Пептид та його застосування
UY37456A (es) Inmunoglobulinas y sus usos
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
AR101742A1 (es) Agonista del receptor de calcitonina y amilina
CL2020000897A1 (es) Composición de proteínas de guisante que tiene calidad nutricional mejorada.
WO2018075692A3 (en) ANTIBODY CONSTRUCTIONS
MX2020010881A (es) Construcciones de anticuerpos anti-ror.